Ardelyx (NASDAQ:ARDX) Insider Joseph James Reilly Sells 3,982 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX) insider Joseph James Reilly sold 3,982 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $15,370.52. Following the sale, the insider owned 145,854 shares in the company, valued at approximately $562,996.44. This trade represents a 2.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ardelyx Stock Performance

Shares of ARDX opened at $3.78 on Wednesday. Ardelyx, Inc. has a 1 year low of $3.72 and a 1 year high of $8.40. The stock has a market capitalization of $941.94 million, a PE ratio of -17.18 and a beta of 0.70. The company has a debt-to-equity ratio of 1.69, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a 50-day simple moving average of $4.97 and a 200-day simple moving average of $5.75.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $120.88 million for the quarter, compared to analysts’ expectations of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%.The firm’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) earnings per share. On average, analysts predict that Ardelyx, Inc. will post -0.2 earnings per share for the current fiscal year.

Key Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
• Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
• Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Knott David M Jr acquired a new stake in shares of Ardelyx during the first quarter worth about $1,240,000. AIGH Capital Management LLC purchased a new position in shares of Ardelyx in the 2nd quarter valued at approximately $16,320,000. Rubric Capital Management LP acquired a new position in shares of Ardelyx in the first quarter valued at approximately $11,147,000. Clay Northam Wealth Management LLC acquired a new position in shares of Ardelyx in the second quarter valued at approximately $1,704,000. Finally, Vanguard Group Inc. raised its stake in shares of Ardelyx by 3.3% during the fourth quarter. Vanguard Group Inc. now owns 18,979,483 shares of the biopharmaceutical company’s stock worth $110,650,000 after purchasing an additional 610,162 shares during the last quarter. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Piper Sandler decreased their price objective on shares of Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Monday, August 17th. Citigroup cut their target price on Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Weiss Ratings downgraded Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. Wedbush reissued an “outperform” rating and issued a $9.00 target price on shares of Ardelyx in a research report on Tuesday, August 18th. Finally, LADENBURG THALM/SH SH started coverage on Ardelyx in a research note on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.90.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.